News & Updates

Treatment with trastuzumab deruxtecan (T-DXd) demonstrates efficacy in patients with metastatic hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2–) breast cancer but may result in adverse events, such as interstitial lung disease (ILD), suggests a study.

Treatment with sacituzumab govitecan (SG), a novel antibody-drug conjugate, provides survival benefits in women diagnosed with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2–) breast cancer, reports a study.

Patients with stage III melanoma show inconsistent use of adjuvant immunotherapy despite its survival benefits, according to a study.